Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy

Liver International

Volumn 34, Issue 7, 2014, Pages 1018-1024

  Crismale, James F ^a   Martel Laferrière, Valérie ^a   Bichoupan, Kian ^a   Schonfeld, Emily ^a   Pappas, Alexis ^a   Wyatt, Christina ^a   Odin, Joseph A ^a   Liu, Lawrence U ^a   Schiano, Thomas D ^a   Perumalswami, Ponni V ^a   Bansal, Meena ^a   Dieterich, Douglas T ^a   Branch, Andrea D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anaemia; Diabetes mellitus; Hepatitis C virus; Pegylated interferon; Ribavirin; Telaprevir; Triple therapy

Indexed keywords

ALPHA INTERFERON; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN; TELAPREVIR;

ANEMIA; DIABETES MELLITUS, TYPE 2; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; RISK; RISK FACTOR; STATISTICAL MODEL;

ANEMIA; DIABETES MELLITUS, TYPE 2; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; ODDS RATIO; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 84904501123     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12342     Document Type: Article

References (32)

1. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
2. Burney T, Dusheiko G. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients. Expert Review of Anti-infective Therapy 2010; 9: 151-60.
3. Aghemo A, Degasperi E, Colombo M. Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials. Digestive and Liver Disease 2013; 45: 1-7.
4. FDA. Highlights of Prescribing Information for Incivek. 2012 [cited 2013 March 29]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201917s007lbl.pdf.
5. Bernstein D, Kleinman L, Barker CM, et al. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704-8.
6. Sulkowski M, Reddy R, Afdhal N, et al. Anemia had no Effect on Efficacy Outcomes in Treatment-naive Patients who Received Telaprevir-based Regimen in the ADVANCE and ILLUMINATE Phase 3 Studies. J Hepatol 2011; 54 (Suppl 1) S195.
7. Hynicka LM, Heil EL. Anemia management in patients with chronic viral hepatitis C. The Annals of Pharmacotherapy 2013; 47: 228-36.
8. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the american association for the study of liver diseases. Hepatology 2011; 54: 1433-44.
9. Bennett C, Silver S, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914-24.
10. Squires JE. Risks of Transfusion. South Med J 2011; 104: 762-9.
11. FDA Antiviral Drugs Advisory Committee Breifing Document: Telaprevir 375-mg Film-Coated Tablet for the Treatment of Genotype 1 Chronic Hepatitis C. 2011 [cited 2012 November 20]; Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM252562.pdf
12. Butt AA, Umbleja T, Andersen JW, et al. The incidence, predictors and management of anaemia and its association with virological response in HCV/HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin. Aliment Pharmacol Ther 2011; 33: 1234-44.
13. Jacobson IM, Kowdley KV, Kwo PY. Anemia management in the era of triple combination therapy for chronic HCV. Gastroenterology and Hepatology 2012; 8: 1-16.
14. DAIDS Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. 2009 [cited 2013 March 29]; Available from: http://rsc.tech-res.com/document/safetyandpharmacovigilance/table_for_grading_severity_of_adult_pediatric_adverse_events.doc.
15. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12.
16. Hsieh YY, Tung SY, Lee K, et al. Routine blood tests to predict liver fibrosis in chronic hepatitis C. World J Gastroenterol 2012; 18: 746-53.
17. FDA Highlights of Prescribing Information for COPEGUS. 2011 [cited 2013 August 27]; Available from: www.accessdata.fda.gov/drugsatfda_docs/label/…/021511s023lbl.pdf.
18. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
19. Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004; 40: 1450-8.
20. McHutchison JG, Manns MP, Longo DL. Definition and Management of Anemia in Patients Infected with Hepatitis C Virus. Liver International 2006; 26: 389-98.
21. Mauss S Substantial Renal Impairment is not Infrequent in HCV Patients Under Triple Therapy with Telaprevir or Boceprevir. In: Samuel D, ed. The International Liver Congress 2013. Amsterdam, The Netherlands: European Association for the Study of the Liver; 2013; S358.
22. Cunningham M, Foster G. Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. Therap Adv Gastroenterol 2012; 5: 139-51.
23. Hu C-C, Weng C-H, Lin C-L, et al. Predictors of Changes in Hemoglobin Levels in Patients with Chronic Hepatitis C Treated with Ribavirin Plus Pegylated Interferon-α. Ren Fail 2012; 34: 429-34.
24. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for Chronic hepatitis C. Nature 2010; 464: 405-8.
25. Hitomi Y, Cirulli ET, Fellay J, et al. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 2011; 140: 1314-21.
26. Suzuki F, Suzuki Y, Akuta N, et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011; 53: 415-21.
27. Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010; 139: 1181 9. e2
28. Thomas MC, MacIsaac RJ, Tsalamandris C, et al. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care 2003; 26: 1164-9.
29. Deray G, Heurtier A, Grimaldi A, et al. Anemia and Diabetes. Am J Nephrol 2004; 24: 522-6.
30. Vlahakos DV, Marathias KP, Madias NE. The Role of the renin-angiotensin system in the regulation of erythropoiesis. Am J Kidney Dis 2010; 56: 558-65.
31. Raptis AE, Bacharaki D, Mazioti M, et al. Anemia due to coadministration of renin-angiotensin-system inhibitors and PPARγ agonists in uncomplicated diabetic patients. Exp Clin Endocrinol Diabetes 2012; 120: 416-9.
32. Kashyap A, Kashyap S. Haemolytic anaemia due to metformin. Postgrad Med J 2000; 76: 125-6.